

Lycopene and Cardiovascular Diseases: A Review of the Literature

Towhid Hasan, Marjia Sultana

Institute of Nutrition and Food Science, University of Dhaka, Dhaka-1000, Bangladesh

Corresponding Author: Towhid Hasan

ABSTRACT

Cardiovascular diseases (CVD) are the leading causes of human disability and premature death throughout the world. Diet has a direct link with the development of CVD and so dietary change is the current approach for the prevention of CVD that is to increase the consumption of fruits and vegetables as good sources of several antioxidant phytochemicals, e.g. carotenoids. Lycopene, the most abundant carotenoid in tomatoes and tomato products has gained profuse attention in recent years for its health beneficial role, especially those related to its effects as an antioxidant and its protective role against CVD. So, the objective of this review is to assess the effect of lycopene in CVD and/or CVD risk factors studying epidemiological, clinical and biochemical data. Among twenty-three epidemiological studies investigating the association between lycopene and CVD, eight studies have found no association whereas other fifteen studies have indicated an inverse association. In case of *in vivo* and *in vitro* cell culture studies, the results are still inconsistent; some provide evidence in favor of lycopene or tomato supplementation to reduce the prognosis of CVD and others do not support the cardio protective role of lycopene. In contrast, animal studies have provided a more vivid result, most have shown a favorable effect of lycopene towards preventing CVD risk. In summary, ignoring the controversies, there lies a demand for more specific and focused research on lycopene, particularly to have a better and comprehensive understanding of lycopene's role in human health and disease for a better-quality life.

Key words: Carotenoids, lycopene, tomatoes, cardiovascular diseases.

INTRODUCTION

Worldwide, cardiovascular diseases (CVD) are the leading causes of human morbidity and mortality and approximately 31% (17.5 million) of all global deaths are attributed to CVD. [1] The current course of the diseases is expected to cause nearly 25 million deaths per year by 2020. [2] The term CVD refers to a group of disorders that includes coronary heart disease (CHD) (myocardial infarction [MI], angina pectoris, coronary insufficiency, and coronary death), cerebrovascular diseases (stroke and transient ischemic attacks

[TIA]), peripheral vascular disease (PVD), congestive heart failure (CHF), hypertension, valvular and congenital heart disease. [3]

Generally, age and genetic factors are considered as irreversible CVD risk factors. Yet smoking, hypertension, abdominal obesity, abnormal lipid profile, diabetes mellitus as well as stress, low consumption of fruits and vegetables, and lack of regular physical activity are some of the modifiable factors that have been recognized as the major contributors to cardiovascular death and disability. [2, 4,5]

Evidence from several epidemiological studies has concluded that diet plays a vital role in the progression of CVD, and so dietary modification has gained a profound interest and research are now being centered on identifying the ways of dietary modification for the prevention of CVD. [6] In this context, increased consumption of a diet rich in fruits and vegetables, as being a good source of various antioxidants, is often recommended by health professionals. [5,7]

Plantfoods including fruits and vegetables contain several phytochemicals, many of which are potent antioxidants, with carotenoids as one group of lipophilic compound. [8] Carotenoids, the yellow, orange and red pigment of fruits and vegetables, have been one of the main hubs of research for a long period as CVD-preventive food ingredients because of their antioxidant property. More than 600 carotenoids have been synthesized from plants, algae, and photosynthetic bacteria with about 50 compounds being employed in the human diet. Approximately 12 different carotenoids can be identified in human blood and tissues of which α -carotene, β -carotene, lycopene, β -cryptoxanthin, lutein, and zeaxanthin are the most common. [5, 9, 10] Lycopene is an unsaturated cyclic carotenoid with 11 linear conjugated double bonds which is principally responsible for the distinctive red color of ripe tomatoes, pink grapefruit, watermelon, papaya, guava, and other fruits. Although lacking in provitamin A activity, lycopene is one of the most potent antioxidants among the dietary carotenoids. Owing to have so many conjugated dienes, lycopene has exceptionally powerful singlet oxygen quenching ability, almost twice the ability than that of β -carotene and approximately ten times that of vitamin E. [11-13] Data from epidemiological studies (cross-sectional, case-control and cohort studies), dietary intervention studies, *in vitro* cell culture studies and laboratory animal studies all suggest a supportive role of antioxidants in the prevention of many

chronic diseases including CVD. These findings have generated much scientific interest in antioxidant lycopene as a source of prevention against CVD.

Keeping all this in mind, the current review is undertaken to represent the current understanding of the linkages between the red carotenoid lycopene and prevention of CVD and/or CVD risk factors, extracting information from studies conducted utilizing human as well as experimental animals as subjects.

LYCOPENE AND CARDIOVASCULAR DISEASES

Numerous studies have been conducted over the past decades to conjecture the potential health beneficial role of carotenoids particularly lycopene. Many researchers have found that increased ingestion of tomatoes and tomato products containing lycopene or higher blood (plasma/serum) concentrations of lycopene is associated with the reduced risk of CVD. Despite the fact, lycopene research has got much attention after the indecisive results obtained from the trials with β -carotene and vitamin E supplementation in relation to CVD. In this review, a number of human and animal studies have been evaluated to highlight the relationship between lycopene and CVD and/or CVD risk factors.

Epidemiological studies

The effect of lycopene on CVD and/or CVD risk factors have been assessed in the present review by studying twenty-three epidemiological studies (Table 1). Dietary, serum or plasma, and adipose tissue lycopene concentrations have been measured to examine the effect of lycopene in these disease conditions. Among these, eight studies have found no protective effect of lycopene against CVD and/or CVD risk factors whereas other fifteen studies have indicated the efficacy of lycopene to prevent the risk of CVD.

Table 1: Epidemiological studies identifying the effects of lycopene on CVD and/or CVD risk factors

Authors, year ^[ref]	Study name	Study design, follow-up	Subjects ¹	Outcome ²	Results ³
Gómez-Aracena et al., 1997 ^[14]	European Study of Antioxidants, Myocardial Infarction, and Cancer of the Breast (EURAMIC) Study, Spain	Case-control	100 vs 102 M	MI	Inverse association between adipose tissue lycopene concentration and risk of MI (OR= 0.39; 95% CI=0.13-1.19, P=0.04)
Kohlmeier et al., 1997 ^[15]	European Study of Antioxidants, Myocardial Infarction, and Cancer of the Breast (EURAMIC) Study	Case-control	662 vs 717 M	MI	Inverse association of adipose tissue lycopene concentration with the risk of MI (OR=0.52; 95% CI=0.33-0.82, P=0.005)
Ascherio et al., 1999 ^[16]	Health Professionals Follow-up Study, USA	Prospective observational 8 y	43738 M (40-75 y)	Stroke	No significant association between lycopene intake and incidence of stroke (RR=0.96; 95% CI=0.68-1.36)
Hirvonen et al., 2000 ^[17]	α -Tocopherol, β -Carotene Cancer Prevention (ATBC) Study, Finland	Prospective cohort 6.1 y	26593 M (50-69 y) smoker	Cerebral infarctions	Inverse association between intake of lycopene and the risks for cerebral infarction (RR=0.74; 95% CI=0.59-0.92)
McQuillan et al., 2001 ^[18]	Perth Carotid Ultrasound Disease Assessment Study (CUDAS), Australia	Cross-sectional	1111 (F, M) (27-77 y)	Atherosclerosis (measured by CIMT)	Inverse association between mean CIMT and plasma lycopene in women (P=0.047) but no association in men (P=0.22)
Gianetti et al., 2002 ^[19]	Italy	Case-control	11 vs 11 M (48-66 y)	Atherosclerosis (measured by CIMT)	Inverse relationship of plasma lycopene with IMTmax (r=-0.42; P=0.014)
Hak et al., 2003 ^[20]	Physicians' Health Study (PHS), USA	Prospective Nested case-control 13 y	531 vs 531 M	MI	No association between plasma lycopene and risk of MI (OR=1.43; 95% CI=0.87-2.35)
Osganian et al., 2003 ^[21]	Nurses' Health Study (NHS), USA	Prospective 12 y	73286 F (30-55 y)	CAD	No significant association between intakes of lycopene and risk of CAD (RR=0.93; 95% CI=0.77-1.14)
Sesso et al., 2003 ^[22]	Women's Health Study (WHS), USA	Prospective cohort 7.2 y	39876 F (Middle-aged and older aged)	CVD	No significant association between lycopene and the risk of CVD (RR=0.90; 95% CI=0.69-1.17)
Dwyer et al., 2004 ^[23]	Los Angeles Atherosclerosis Study (LAAS), USA	Prospective	573 (F, M) (40-60 y)	Atherosclerosis (measured by CIMT)	Plasma levels of lycopene were not significantly associated with IMT progression (P=0.89)
Hak et al., 2004 ^[24]	Physicians' Health Study (PHS), USA	Prospective Nested case-control 13 y	297 vs 297 M	Ischemic stroke	Inverse association of lycopene with the risk of ischemic stroke (OR=0.61; 95% CI=0.37-1.00)
Sesso et al., 2004 ^[25]	Women's Health Study (WHS), USA	Nested case-control 4.8 y	483 vs 483 M	CVD	Inverse association between lycopene concentration and the risk of CVD (RR=0.66; 95% CI=0.47-0.95)
Sesso et al., 2005 ^[26]	Physicians' Health Study (PHS), USA	Prospective Nested case-control 13 y	499 vs 499 M	CVD	No association of lycopene with the risk of CVD (RR=1.03; 95% CI=0.65-1.64)
Ito et al., 2006 ^[27]	Japan	Follow-up 11.9 y	3061 (F, M) (39-80 y)	CVD mortality	Significant inverse association between high serum lycopene value and the risk for CVD mortality (HR=0.73; 95% CI=0.55-0.97)
Tavani et al., 2006 ^[28]	Italy	Case-control 8 y	760 vs 682 (F, M)	AMI	No association between lycopene and the risk of AMI (OR=1.19; 95% CI=0.82-1.70)
Hozawa et al., 2009 ^[29]	Coronary Artery Risk Development in Young Adults (CARDIA) Study	Prospective 20 y	4412 (F, M) (18-30 y)	Hypertension	No significant relation between lycopene and incident hypertension (RH=0.98; 95% CI=0.92-1.05)
Riccioni et al., 2009 ^[30]	Asymptomatic Carotid Atherosclerotic Disease in Manfredonia (ACADIM) Study, Italy	Cross-sectional	640 F, M	Atherosclerosis (measured by CIMT)	Plasma lycopene was significantly lower in participants with carotid atherosclerosis (P<0.001)
Kim et al., 2010 ^[31]	Cardiovascular-Aging Control Study, Korea	Cross-sectional	264 F (31-75 y)	Arterial stiffness (measured by baPWV)	Inverse relationship between circulating lycopene and baPWV (β = -0.221; 95% CI=-0.215; -0.012, P=0.029)
Karppi et al., 2011 ^[32]	Kuopio Ischaemic Heart Disease Risk Factor (KIHD) Study	Cohort	1212 M (61-80 y)	Atherosclerosis (measured by CIMT)	Inverse association of plasma lycopene concentrations with carotid atherosclerosis (r=-0.138; P<0.001)
Yeo et al., 2011 ^[33]	Korea	Cross sectional 1 y	299 M	Arterial stiffness (measured by baPWV)	Inverse correlation of baPWV with serum lycopene (r=-0.136; P<0.05)
Karppi et al., 2012 ^[34]	Kuopio Ischaemic Heart Disease Risk Factor (KIHD) Study	Prospective 12.1 y	1031 M (46-65 y)	Stroke	Inverse association between serum lycopene and the risk of any stroke (HR=0.45; 95% CI=0.25-0.95, P=0.036)
Xu et al., 2012 ^[35]	Beijing Atherosclerosis Study	Case-control	40 vs 40	Atherosclerosis	Lycopene was inversely associated with VCAM-1 (P=0.011) and LDL (P=0.046)

Table 1: Continued....					
Biddle et al., 2013 [36]	Kentucky, Indiana and Georgia	Prospectively	212 (M, F) Patients with HF	HF	Higher lycopene intake was associated with longer cardiac event-free survival compared with lower lycopene intake (P=0.003) in patients with HF

¹M: Male, F: Female; y: Year. ²AMI: Acute myocardial infarction, baPWV: Brachial-ankle pulse wave velocity, CAD: Coronary artery disease, CIMT: Carotid Intima Media Thickness; HF: Heart Failure, IMTmax: Carotid maximum intima-media thickness, MI: Myocardial infarction. ³ β :Regression coefficients, HR: Hazard ratio, LDL: Low-density lipoprotein, OR: Odds ratio, r: Correlation coefficient, RH=Relative Hazards, RR: Relative risk, VCAM-1: Vascular cell adhesion molecule.

Table 2: *In vivo* intervention studies investigating the effects of lycopene (or tomatoes or tomato products) supplementation on CVD and/or CVD risk factors

Authors, year [ref]	Subjects ¹	Lycopene supplementation			Results ²
		Form	Dose (mg/day)	Duration	
Agarwal and Rao, 1998 [37]	19 (10 M, 9 F) (25-40 y)	Spaghetti sauce Tomato juice Lycopene capsule	39.2 50.4 75	1 week	Significant decrease in serum lipid peroxidation and LDL oxidation
Bub et al., 2000 [38]	23 M (27-40 y)	Tomato juice	40	2 weeks	18% reduction in LDL oxidation (P<0.001) Reduction in lipid peroxidation
Carroll et al., 2000 [39]	47 (25 F, 22 M) (≥ 65 y)	Lycopene capsule	13.3	12 weeks	No reduction or delay of LDL oxidation (P=0.397)
Hininger et al., 2001 [40]	175 M (25-45 y)	Lycopene capsule	15	12 weeks	No significant effect on LDL oxidation or LDL polyunsaturated/saturated fatty acid ratio No change in antioxidant enzyme (SOD, GSH-Px) activities
Visioli et al., 2003 [41]	12 F (22-38 y)	Different tomato products (raw, sauce, and paste)	8	3 weeks	Significant reduction in LDL oxidation (P<0.001) No significant change of plasma antioxidant capacity Significantly decrease in urinary excretion of 8- <i>epi</i> -PGF _{2α}
Riso et al., 2004 [42]	12 F	Different tomato products (raw, sauce, and paste)	8	3 weeks	24% reduction in DNA damage (P<0.05) No significant reduction in lipid peroxidation (measured by MDA)
Tyssandier et al., 2004 [43]	20 F (20-40 y)	Tomato puree	13.6	3 weeks	No significant effect on plasma TAOC
Bub et al., 2005 [44]	22 M	Tomato juice	37	2 weeks	Significant reduction in lipid peroxidation No effect on LDL oxidation
Porrini et al., 2005 [45]	26 (M, F)	Lyc-O-Mato	5.7	26 days	Significantly reduction (about 42%) in DNA damage (P<0.0001) in lymphocytes subjected to oxidative stress
Bose and Agrawal, 2006 [46]	30 (M, F) (35-55 y) type 2 diabetic patients	Ripe tomatoes (cooked)		60 days	Significant improvement (P<0.001) in antioxidant enzymes (SOD, GSH-Px, GR and GSH) levels and decrease in lipid peroxidation (MDA) rate No significant changes in lipid profile (TG, HDL, LDL)
Engelhard et al., 2006 [47]	31 (M, F) (30-70 y) grade I hypertension	Lyc-O-Mato	15	8 weeks	Significant decrease in systolic (P<0.001) and diastolic (P<0.05) blood pressure No significant changes in lipid parameters Significant decrease in lipid peroxidation
Madrid et al., 2006 [48]	17 (9 M, 8 F)	Tomato juice	18	7 days	No significantly change in TRAP, catalase and SOD Significant increase in HDL cholesterol (P<0.002)
Paterson et al., 2006 [49]	36 (12 M, 24 F) (20-70 y)	Tomato soup	10	4 weeks	No effect on plasma antioxidant status No effect on plasma total, HDL, and LDL cholesterol level
Riso et al., 2006 [50]	26 (F, M)	Lyc-O-Mato	5.7	26 days	34.4% reduction in TNF- α production by whole blood No significant lymphocyte DNA damage
Sánchez-Moreno et al., 2006 [51]	12 (6 M, 6 F)	Tomato soup (gazpacho)		14 days	Significantly decrease of 8- <i>epi</i> -PGF _{2α} , PGE ₂ and MCP-1 concentrations No effect on TNF- α , IL-1 β and IL-6
Zhao et al., 2006 [52]	37 (50-70 y) post-menopausal women	Lycopene capsule	4 or 8	56 days	Significant reduction in endogenous DNA damage (P<0.01)
Blum et al., 2007 [53]	103 (35 M, 68 F)	Tomato		30 days	No significant change of inflammatory markers (hs-CRP, E-selectin and ICAM-1)
Bose and Agrawal, 2007 [54]	30 (M, F) (35-55 y) grade I hypertensive patients	Ripe tomatoes (cooked)	25	60 days	Significant reduction in MDA levels indicating a lower rate of lipid peroxidation (P<0.001) Significant increase in levels of antioxidant enzymes (SOD, glutathione reductase, GSH-Px) (P<0.001) No significant changes in lipid profile (P>0.10)
Neyestani et al., 2007 [55]	35 (M, F) (35-70 y) type 2 diabetic patients	Lycopene	10	8 weeks	Significant decrease in serum MDA level while increase in TAOC/MDA indicating attenuation of oxidative stress
Silaste et al., 2007 [56]	21 (15 F, 6 M) (20-49 y)	Tomato juice and tomato ketchup	27	3 weeks	Significant reduction in plasma total and LDL cholesterol level Significant decrease in LDL oxidation
Denniss et al., 2008 [57]	27 (18 M, 9F)	Lyc-O-Mato	80	1 week	No effect on biomarkers of vascular oxidative stress (measured by MDA) and inflammation (measured by CRP)

Table 2: Continued...

Table 2: Continued...					
Devaraj et al., 2008 ^[58]	77 (19 M, 58 F)	Lycopene capsule	6.5, 15 or 30	8 weeks	Significant decrease in DNA damage by the comet assay (P<0.007), and a significant decrease in urinary 8-OHdG versus baseline (P<0.0002), with 30 mg lycopene/day No significant inter- or intra-group differences for lipid profile, or other biomarkers of lipid peroxidation at any dose/time point
Lee et al., 2009 ^[59]	10 M	Tomato sauce	30	48 hours	No change in plasma levels of F ₂ -isoprostanes, hydroxy-eicosatetraenoic acid products, allantoin and urinary 8-OHdG Significant decrease in urinary F ₂ -isoprostanes level (P<0.05)
Markovits et al., 2009 ^[60]	16 (8 M, 8F)	Lyc-O-Mato	30	4 weeks	No change in the markers of inflammation and oxidation products (CRP, IL-6, TNF- α , conjugated dienes)
Paran et al., 2009 ^[61]	50 (26 M, 24 F) (46-66 y) grade I hypertensive patients	Lyc-O-Mato	15	6 weeks	Significant reduction of systolic (P<0.001) and diastolic (P=0.001) blood pressure
Ried et al., 2009 ^[62]	36 (19 M, 17 F) pre-hypertensive patients	Lyc-O-Mato	15	8 weeks	No significant changes of blood pressure over time within groups and between groups in pre-hypertensive patients
Kim et al., 2011 ^[63]	126 M (22-57 y)	Lycopene	6 or 15	8 weeks	Significant dose dependent decrease in lymphocyte DNA damage and increase in plasma SOD activity Significant decrease in systolic blood pressure (P=0.037), plasma concentrations of ICAM-1 (P=0.008) and VCAM-1 (P=0.02), and serum concentrations of hs-CRP (P=0.046), and increase in plasma LDL particle size with 15 mg lycopene only
Shidfar et al., 2011 ^[64]	32 M (40-60 y) type 2 diabetic patients	Raw tomato		8 weeks	Significant decreases in systolic (P=0.0001) and diastolic (P=0.0001) blood pressure Significant increase in apoA-1 (P<0.013)
Stangl et al., 2011 ^[65]	31 F non-smoking post-menopausal	Tomato puree	46	24 h and 7 days	No effects on endothelium-dependent or -independent dilation of the brachial artery on acute or long term consumption
Burton-Freeman et al., 2012 ^[66]	25 (13 M, 12 F) (19-35 y)	Tomato paste	27	6 h	Significantly reduction in serum oxidized LDL cholesterol and IL-6 level No effect on hs-CRP and TNF- α
Thies et al., 2012 ^[67]	225 (94 M, 131 F) (40-65 y) moderately overweight	Tomato	32-50	12 weeks	No significant change in inflammatory markers, lipid concentrations and arterial stiffness
		Lycopene capsule	10		
Xaplanteris et al., 2012 ^[68]	19 (8 M, 11 F) (26-52 y)	Tomato paste	33.3	14 days	Significant increase in FMD leading to improved endothelial function (P<0.05) Significant decreased in TOS compared with baseline (P=0.038)
Abete et al., 2013 ^[69]	30 (9 M, 21 F) (18-50 y)	Tomato sauce	12.3 or 27.2	4 weeks	Significant reduction in oxidized-LDL cholesterol levels (P<0.05) in high- lycopene tomato sauce consumption
Cuevas-Ramos et al., 2013 ^[70]	50 (9 M, 41 F) overweight	Tomato (uncooked)		4 weeks	Significant increase in serum HDL cholesterol levels in overweight women (P<0.0001)
Ghavipour et al., 2013 ^[71]	106 F (20-40 y) obese or overweight	Tomato juice	37	20 days	Significant decrease in IL-8 and TNF- α in overweight only Significant decrease in serum IL-6 concentration in obese only
McEneny et al., 2013 ^[72]	54 (M, F) (40-65 y) moderately overweight	Tomato	32-50	12 weeks	Significant decrease in systemic SAA level leading to reduced inflammation and restoring some of HDL's antiatherogenic properties
		Lycopene	10		
Tsitsimpikou et al., 2014 ^[73]	27 (24 M, 3 F)	Tomato juice	5	2 months	Significantly decrease of TNF- α levels (P=0.021) Significant (P=0.026) improvement in the endothelial function (measured by ADMA) Significant decrease in serum LDL-cholesterol (P<0.001) and a slight increase in HDL cholesterol levels (P=0.049)
Burton-Freeman et al., 2016 ^[74]	53 (21-70 y) overweight or obese	Tomato		6 weeks	Significant decrease in diastolic blood pressure but no effect on systolic blood pressure No effect on plasma lipid profile (TG, LDL and HDL) or inflammatory markers (hs-CRP, TNF- α , IL-6)

¹M: Male, F: Female, y: Year. ²8-*epi*-PGF_{2 α} : 8-*epi*-prostaglandin F_{2 α} , 8-OHdG: 8-hydroxy deoxoguanosine, ADMA: Asymmetric dimethyl arginine, apoA-1: Apolipoprotein A-1, CRP: C-reactive protein, FMD: Flow-mediated dilatation, GSH-Px: Glutathione peroxidase, GR: Glutathione reductase, HDL: High-density lipoprotein, hs-CRP: High sensitivity C reactive protein, ICAM-1: Intercellular adhesion molecule-1, IL-1 β : Interleukin-1 β , IL-6: Interleukin-6, IL-8: Interleukin-8, MCP-1: Monocyte chemotactic protein, MDA: Malondialdehyde, PGE₂: Prostaglandin E₂, SAA: Serum amyloid A, SOD: Superoxide dismutase, TAOC: Total antioxidant capacity, TNF- α : Tumor necrosis factor alpha, TOS: Total oxidative status, TRAP: Total peroxyl radical trapping.

Human interventional studies

To date, numerous interventional (both *in vivo* and *in vitro*) studies have been published investigating the effects of lycopene (or tomatoes or tomato products) supplementation on CVD and/or CVD risk factors. Studies on the supplementation with lycopene, singly or in combination with other carotenoids and nutrients, for variable periods of time were performed in order to evaluate the possible effects on CVD and/or related pathophysiological factors or markers.

In vivo studies. A total of thirty-eight clinical trials have been analyzed in this review on the effect of dietary supplementation with lycopene, or tomatoes and tomato products on CVD and/or CVD risk factors (Table 2). The supplements used as lycopene source were raw tomato (both cooked and uncooked), tomato juice, tomato paste, tomato sauce/ketchup, tomato puree, tomato soup, and lycopene capsule (as Lycopene, which is a tomato lycopene complex containing lycopene and several phytonutrients including phytoene, phytofluene, β -carotene, tocopherols, and phytosterols). In these studies, the duration of lycopene supplementation was as low as 6 h to 12 weeks long. Lycopene doses ranged from 4 mg/day lycopene (for 8

weeks) to 80 mg/day (for 1 week). The biomarkers assessed as emerging CVD risk factors were oxidative stress and antioxidant enzyme activity, inflammation, blood pressure, endothelial function, lipid profile and lipid peroxidation. Among the analyzed studies, some provided evidence in favor of lycopene or tomato supplementation to reduce the prognosis of CVD and others did not support the cardioprotective effect of lycopene.

In vitro studies. Advances in basic and clinical science in the last years have elicited *in vitro* antioxidant potency of lycopene derived from foods or supplements. In the present review, the role of lycopene in the different risk factors that contribute to CVD has been discussed studying eight such *in vitro* cell culture studies (Table 3). Different studies examined different types of human cells with different lycopene doses. Investigation of these studies illuminated that lycopene might have a preventive role in the development of CVD by reducing oxidative stress, inflammation, platelet aggregation, expression of HMG-CoA reductase, intracellular cholesterol levels and lipid peroxidation in a dose- and time-dependent manner in the examined cells.

Table 3: *In vitro* cell culture studies assessing the potency of lycopene in the different risk factors of CVD

Authors, year ^[ref]	Cell type	Lycopene dose ($\mu\text{mol/L}$)	Results ¹
Hsiao et al., 2005 ^[75]	Human platelet	2-12	Dependent inhibition of platelet aggregation by inhibiting the activation of phospholipase C, and activating cyclic GMP/nitrate formation
Safari, 2007 ^[76]	Human plasma	0-200	Significant inhibition of the copper-catalyzed oxidation of LDL in a dose-dependent manner ($P < 0.01$) Suppression of the formation of lipid peroxides and TBARS
Hung et al., 2008 ^[77]	Human umbilical vein endothelial cells (HUVECs) and THP-1 monocytes		Inhibition of TNF- α -induced NF- κ B activation, ICAM-1 and VCAM-1 expression, and monocyte-endothelial interaction No effect on COX-2 and PECAM-1 expression
Tang et al., 2009 ^[78]	Vascular endothelial cells (ECV304 cells)	0.2-20	Protection against oxidative attacks by H ₂ O ₂ (measured by reduced MDA level) Significant reduction of the apoptosis ration of oxidative injured cells Downregulation of the expression of p53 and caspase-mRNA induced by H ₂ O ₂
Palozza et al., 2010 ^[79]	Human THP-1 macrophages	0.5-2	Significant reduction of the increase in ROS production and in 8-OHdG formation induced by the oxysterol in a dose-dependent manner Significant inhibition of 7-KC-induced apoptosis by limiting caspase-3 activation
Palozza et al., 2011 ^[80]	Human THP-1 macrophages	0.5-2	Reduction of the intracellular total cholesterol content through the reduction of HMG-CoA reductase expression
Di Tomo et al., 2012 ^[81]	Human umbilical vein endothelial cells (HUVECs)	2.5	Significant reduction of TNF- α -induced inflammation
Sung et al., 2015 ^[82]	Human umbilical vein endothelial cells (HUVECs)	3-10	Inhibition of cyclic strain-induced ET-1 expression through the suppression of ROS generation and induction of HO-1

¹7-KC: 7-ketocholesterol, COX-2: Cyclooxygenase-2, ET-1: Endothelin-1, H₂O₂: Hydrogen peroxide, HMG-CoA: 3-hydroxy-3-methylglutaryl-coenzyme A, HO-1: Heme oxygenase-1, PECAM-1: Platelet-endothelial cell adhesion molecule, ROS: Reactive oxygen species, TBARS: Thiobarbituric acid-reactive substances.

Animal studies

Animal models used to conduct research are typically inbred animals, thus reducing genetic variation and producing clearer results. Here, available evidence for a direct regulation of lycopene on the development of the risk of CVD has been reviewed using results from the following fourteen animal studies (Table 4). Type of animal models, lycopene doses and duration

of the supplementation were different among the studies. Findings of all of the studies revealed a favorable effect of lycopene towards preventing CVD risk except Frederiksen et al., study where Male Watanabe Heritable Hyperlipidemic (WHHL) rabbits were examined for a long period (16 weeks) and did not find any significant effect of lycopene on the markers of CVD.

Table 4: Animals studies showing the efficacy of lycopene supplementation on CVD risk factors

Authors, year ^[ref]	Animal model	Lycopene supplementation		Results ¹
		Dose/day	Duration	
Hassan and Edrees, 2004 ^[83]	Male <i>Rattus norvegicus</i>	1 mg/kg	4 weeks	Significant decrease in serum total lipids, total cholesterol and LDL cholesterol level
Bansal et al., 2006 ^[84]	Male Albino Wistar rats	1 mg/kg	31 days	Significant reduction (P<0.001) of ischemia-reperfusion induced lipid peroxidation (measured by reduction in MDA levels) Significant increase in level of GSH content (P<0.05) and antioxidant enzyme GSH-Px (P<0.001)
Sahin et al., 2006 ^[85]	Female Japanese quail	100 mg/kg	70 days	Significant decrease in serum MDA level (P<0.05) Decrease in serum cholesterol level (P<0.05)
Frederiksen et al., 2007 ^[86]	Male Watanabe Heritable Hyperlipidemic (WHHL) rabbits	15 mg/100 g diet	16 weeks	No effect on cholesterol and TG levels in total plasma, lipoprotein fractions and on aortic atherosclerosis No effect on oxidation of lipids in unfractionated plasma
Hu et al., 2008 ^[87]	Male New Zealand white rabbits	4 mg/kg and 12 mg/kg	4 and 8 weeks	Decrease in the levels of total cholesterol, total TG, LDL cholesterol, malonaldehyde, oxidized LDL and IL-1 increased and total antioxidant capacity and nitric oxide (P<0.05) Reduction in the formation of atherosclerotic plaques in the aorta
Kuhad et al., 2008 ^[88]	Male Albino mice of Laca strain	1, 2 and 4 mg/kg	4 and 8 weeks	Significant dose dependent decrease in TNF- α levels and serum nitrite levels in diabetes mice
Vergheze et al., 2008 ^[89]	Male New Zealand white rabbits	42.6, 85.2, and 127.8 ppm	12 weeks	Decrease in serum total cholesterol and LDL cholesterol levels and increase in HDL cholesterol level (P \leq 0.05) Reduction in hepatic HMG-CoA reductase activity (P \leq 0.001) and ACAT activity (P \leq 0.05) 64.3% reduction in the formation of atherosclerotic plaques in the aorta
Verschuren et al., 2011 ^[90]	Female ApoE*3Leiden transgenic mice	3.75 mg	6 weeks	Significant decrease in cholesterol and TG level in plasma
Lorenz et al., 2012 ^[91]	Male New Zealand White (NZW) rabbits	5 mg/kg	4 weeks	Significant reduction in serum total and LDL cholesterol levels as well as cholesteryl ester in the aorta
Mohamadin et al., 2012 ^[92]	Adult male Sprague-Dawley rats	4 mg/kg	21 days	Significant amelioration of lysosomal membrane damage as well as the alterations in cardiac enzymes, lipid profile and oxidative stress markers in ISO rats
Ojha et al., 2013 ^[93]	Wistar male albino rats	0.5, 1.0 and 1.5 mg/kg	30 days	Significant (P<0.05) attenuation of ISP-induced cardiac dysfunction evidenced by improved SAP, DAP, MAP, (\pm)LVdP/dt (at 1.0 and 1.5 mg/kg doses), and HR (at all doses) Significant (P< 0.05) prevention of the depletion of antioxidants (SOD, CAT, GSH-Px and GSH), myocyte injury marker enzymes (CK-MB and LDH) Inhibition of lipid peroxidation and MDA formation in the heart
Wang et al., 2014 ^[94]	Male Sprague-Dawley rats	40 mg/kg	28 days	Improvement in the cardiac function and ventricular remodeling by inhibition of p38 activation and MMP-9 expression
Martin-Pozuelo et al., 2015 ^[95]	Male Sprague-Dawley rats	105 mg/kg	5 weeks	Significant improvement in the plasma HDL level (P<0.05)
Vilahur et al., 2015 ^[96]	Female swine	21.5 mg	10 days	Reduction in oxidized LDL concentration Increase in endothelial eNOS expression and activity Improvement in HDL functionality

¹(\pm)LVdP/dt: Peak positive and negative left ventricular end-diastolic pressure development, ACAT: Acyl-CoA-cholesterol acyltransferase, CAT: Catalase, CK-MB: Creatine phosphokinase-MB, DAP: diastolic arterial blood pressure, eNOS: Endothelial nitric oxide synthase, GSH: Reduced glutathione, HR: Heart rate, ISP: Isoproterenol, LDH: Lactate dehydrogenase, LVEDP: Left ventricular end-diastolic pressure, MAP: Mean arterial blood pressure, MMP-9: Matrix metalloproteinase 9, SAP: Systolic arterial blood pressure.

CONCLUSION

It has been demonstrated that diet plays a dual role both in the development

and also in the prevention of many chronic diseases like CVD. As fruits and vegetables are great sources of many antioxidants,

higher dietary intake is advised nowadays to prevent the development of heart diseases. So, the area of interest of this review was on examining the available studies assessing the effectiveness of lycopene on CVD and/or CVD risk factors. Nonetheless, there lies incongruity between epidemiological and human intervention trials, there is still some promising evidence for a role of lycopene for the prevention of CVD. Discrepancies occurred may be due to age and gender factors, number of subjects, duration of studies, presence or absence of other nutrients (e.g. vitamin A, E, and C) etc. On the other hand, a clearer relationship between lycopene intake and reduction of risk of CVD was found in animal studies. However, the evidence found so far is mainly suggestive. All of the studies have also failed to provide any recommendation on optimal dose or amount of lycopene or tomato and tomato products consumption at individual or population level.

In a nutshell, research with lycopene needs to be expanded, along with other natural products having health beneficial effect, and there exist ample opportunities for that. More specific and focused research, therefore, will provide a better and comprehensive understanding of lycopene's role not only in CVD but also in other chronic diseases for a better-quality life.

REFERENCES

1. WHO. Cardiovascular diseases (CVDs) [Internet]. World Health Organization; 2016 [updated September 2016; cited 2016 December 15]. Available from: <http://www.who.int/mediacentre/factsheets/fs317/en/>.
2. Dahlof B. Cardiovascular disease risk factors: epidemiology and risk assessment. *The American journal of cardiology*. 2010;105(1 Suppl):3a-9a.
3. Zachariah JP, Vasan RS, D'Agostino RB. The Burden of Increasing Worldwide Cardiovascular Disease. In: Fuster V, Walsh RA, Harrington RA, editors. *Hurst's The Heart*. 1. 13 ed. New York: McGraw-Hill Companies; 2011.
4. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. *Lancet* (London, England). 2004;364(9438):937-52.
5. Bohm V. Lycopene and heart health. *Molecular nutrition & food research*. 2012;56(2):296-303.
6. Willcox JK, Catignani GL, Lazarus S. Tomatoes and cardiovascular health. *Critical reviews in food science and nutrition*. 2003;43(1):1-18.
7. Ruxton CH, Gardner EJ, Walker D. Can pure fruit and vegetable juices protect against cancer and cardiovascular disease too? A review of the evidence. *International journal of food sciences and nutrition*. 2006;57(3-4):249-72.
8. Willcox BJ, Curb JD, Rodriguez BL. Antioxidants in cardiovascular health and disease: key lessons from epidemiologic studies. *The American journal of cardiology*. 2008;101(10a):75d-86d.
9. Britton G. Structure and properties of carotenoids in relation to function. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*. 1995;9(15):1551-8.
10. Voutilainen S, Nurmi T, Mursu J, Rissanen TH. Carotenoids and cardiovascular health. *The American journal of clinical nutrition*. 2006;83(6):1265-71.
11. Di Mascio P, Kaiser S, Sies H. Lycopene as the most efficient biological carotenoid singlet oxygen quencher. *Arch Biochem Biophys*. 1989;274(2):532-8.
12. Rao AV, Ray MR, Rao LG. Lycopene. *Advances in food and nutrition research*. 2006;51:99-164.
13. Arab L, Steck S. Lycopene and cardiovascular disease. *The American journal of clinical nutrition*. 2000;71(6 Suppl):1691S-5S; discussion 6S-7S.
14. Gómez-Aracena J, Sloots L, García-Rodríguez A, Veer vtP, Gómez-Gracia E, García-Alcántara A, et al. Antioxidants in adipose tissue and myocardial infarction in a

- Mediterranean area. The EURAMIC study in M laga. *Nutr Metab Cardiovasc Dis.* 1997;7:376 - 82.
15. Kohlmeier L, Kark JD, Gomez-Gracia E, Martin BC, Steck SE, Kardinaal AF, et al. Lycopene and myocardial infarction risk in the EURAMIC Study. *American journal of epidemiology.* 1997;146(8):618-26.
 16. Ascherio A, Rimm EB, Hernan MA, Giovannucci E, Kawachi I, Stampfer MJ, et al. Relation of consumption of vitamin E, vitamin C, and carotenoids to risk for stroke among men in the United States. *Annals of internal medicine.* 1999;130(12):963-70.
 17. Hirvonen T, Virtamo J, Korhonen P, Albanes D, Pietinen P. Intake of flavonoids, carotenoids, vitamins C and E, and risk of stroke in male smokers. *Stroke; a journal of cerebral circulation.* 2000;31(10):2301-6.
 18. McQuillan BM, Hung J, Beilby JP, Nidorf M, Thompson PL. Antioxidant vitamins and the risk of carotid atherosclerosis. The Perth Carotid Ultrasound Disease Assessment study (CUDAS). *Journal of the American College of Cardiology.* 2001;38(7):1788-94.
 19. Gianetti J, Pedrinelli R, Petrucci R, Lazzarini G, De Caterina M, Bellomo G, et al. Inverse association between carotid intima-media thickness and the antioxidant lycopene in atherosclerosis. *Am Heart J.* 2002;143(3):467-74.
 20. Hak AE, Stampfer MJ, Campos H, Sesso HD, Gaziano JM, Willett W, et al. Plasma carotenoids and tocopherols and risk of myocardial infarction in a low-risk population of US male physicians. *Circulation.* 2003;108(7):802-7.
 21. Osganian SK, Stampfer MJ, Rimm E, Spiegelman D, Manson JE, Willett WC. Dietary carotenoids and risk of coronary artery disease in women. *The American journal of clinical nutrition.* 2003;77(6):1390-9.
 22. Sesso HD, Liu S, Gaziano JM, Buring JE. Dietary lycopene, tomato-based food products and cardiovascular disease in women. *The Journal of nutrition.* 2003;133(7):2336-41.
 23. Dwyer JH, Paul-Labrador MJ, Fan J, Shircore AM, Merz CN, Dwyer KM. Progression of carotid intima-media thickness and plasma antioxidants: the Los Angeles Atherosclerosis Study. *Arteriosclerosis, thrombosis, and vascular biology.* 2004;24(2):313-9.
 24. Hak AE, Ma J, Powell CB, Campos H, Gaziano JM, Willett WC, et al. Prospective study of plasma carotenoids and tocopherols in relation to risk of ischemic stroke. *Stroke; a journal of cerebral circulation.* 2004;35(7):1584-8.
 25. Sesso HD, Buring JE, Norkus EP, Gaziano JM. Plasma lycopene, other carotenoids, and retinol and the risk of cardiovascular disease in women. *The American journal of clinical nutrition.* 2004;79(1):47-53.
 26. Sesso HD, Buring JE, Norkus EP, Gaziano JM. Plasma lycopene, other carotenoids, and retinol and the risk of cardiovascular disease in men. *The American journal of clinical nutrition.* 2005;81(5):990-7.
 27. Ito Y, Kurata M, Suzuki K, Hamajima N, Hishida H, Aoki K. Cardiovascular disease mortality and serum carotenoid levels: a Japanese population-based follow-up study. *Journal of epidemiology / Japan Epidemiological Association.* 2006;16(4):154-60.
 28. Tavani A, Gallus S, Negri E, Parpinel M, La Vecchia C. Dietary intake of carotenoids and retinol and the risk of acute myocardial infarction in Italy. *Free radical research.* 2006;40(6):659-64.
 29. Hozawa A, Jacobs DR, Jr., Steffes MW, Gross MD, Steffen LM, Lee DH. Circulating carotenoid concentrations and incident hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) study. *Journal of hypertension.* 2009;27(2):237-42.
 30. Riccioni G, D'Orazio N, Palumbo N, Bucciarelli V, Ilio E, Bazzano LA, et al. Relationship between plasma antioxidant concentrations and carotid intima-media thickness: the Asymptomatic Carotid Atherosclerotic Disease In Manfredonia Study. *European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and*

- Cardiac Rehabilitation and Exercise Physiology. 2009;16(3):351-7.
31. Kim OY, Yoe HY, Kim HJ, Park JY, Kim JY, Lee S-H, et al. Independent inverse relationship between serum lycopene concentration and arterial stiffness. *Atherosclerosis*. 2010;208(2): 581-6.
 32. Karppi J, Kurl S, Laukkanen J, Rissanen T, Kauhanen J. Plasma carotenoids are related to intima-media thickness of the carotid artery wall in men from eastern Finland. *Journal of internal medicine*. 2011;270(5):478.
 33. Yeo HY, Kim OY, Lim HH, Kim JY, Lee JH. Association of serum lycopene and brachial-ankle pulse wave velocity with metabolic syndrome. *Metabolism*. 2011;60(4):537-43.
 34. Karppi J, Laukkanen JA, Sivenius J, Ronkainen K, Kurl S. Serum lycopene decreases the risk of stroke in men A population-based follow-up study. *Neurology*. 2012;79(15):1540-7.
 35. Xu XR, Zou ZY, Huang YM, Xiao X, Ma L, Lin XM. Serum carotenoids in relation to risk factors for development of atherosclerosis. *Clinical biochemistry*. 2012;45(16-17):1357-61.
 36. Biddle M, Moser D, Song EK, Heo S, Payne-Emerson H, Dunbar SB, et al. Higher dietary lycopene intake is associated with longer cardiac event-free survival in patients with heart failure. *European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology*. 2013;12(4):377-84.
 37. Agarwal S, Rao AV. Tomato lycopene and low density lipoprotein oxidation: a human dietary intervention study. *Lipids*. 1998;33(10):981-4.
 38. Bub A, Watzl B, Abrahamse L, Delincee H, Adam S, Wever J, et al. Moderate intervention with carotenoid-rich vegetable products reduces lipid peroxidation in men. *The Journal of nutrition*. 2000;130(9):2200-6.
 39. Carroll YL, Corridan BM, Morrissey PA. Lipoprotein carotenoid profiles and the susceptibility of low density lipoprotein to oxidative modification in healthy elderly volunteers. *European journal of clinical nutrition*. 2000;54(6):500-7.
 40. Hininger IA, Meyer-Wenger A, Moser U, Wright A, Southon S, Thurnham D, et al. No significant effects of lutein, lycopene or β -carotene supplementation on biological markers of oxidative stress and LDL oxidizability in healthy adult subjects. *Journal of the American College of Nutrition*. 2001;20(3):232-8.
 41. Visioli F, Riso P, Grande S, Galli C, Porrini M. Protective activity of tomato products on in vivo markers of lipid oxidation. *European journal of nutrition*. 2003;42(4):201-6.
 42. Riso P, Visioli F, Erba D, Testolin G, Porrini M. Lycopene and vitamin C concentrations increase in plasma and lymphocytes after tomato intake. Effects on cellular antioxidant protection. *European journal of clinical nutrition*. 2004;58(10):1350-8.
 43. Tyssandier V, Feillet-Coudray C, Caris-Veyrat C, Guillard JC, Coudray C, Bureau S, et al. Effect of tomato product consumption on the plasma status of antioxidant microconstituents and on the plasma total antioxidant capacity in healthy subjects. *Journal of the American College of Nutrition*. 2004;23(2):148-56.
 44. Bub A, Barth SW, Watzl B, Briviba K, Rechkemmer G. Paraoxonase 1 Q192R (PON1-192) polymorphism is associated with reduced lipid peroxidation in healthy young men on a low-carotenoid diet supplemented with tomato juice. *British journal of nutrition*. 2005;93(03):291-7.
 45. Porrini M, Riso P, Brusamolino A, Berti C, Guarnieri S, Visioli F. Daily intake of a formulated tomato drink affects carotenoid plasma and lymphocyte concentrations and improves cellular antioxidant protection. *British Journal of Nutrition*. 2005;93(01):93-9.
 46. Bose K, Agrawal B. Effect of long term supplementation of tomatoes (cooked) on levels of antioxidant enzymes, lipid peroxidation rate, lipid profile and glycated haemoglobin in Type 2 diabetes mellitus. *West Indian Medical Journal*. 2006;55(4):274-8.
 47. Engelhard YN, Gazer B, Paran E. Natural antioxidants from tomato

- extract reduce blood pressure in patients with grade-1 hypertension: A double-blind, placebo-controlled pilot study. *American Heart Journal*. 2006;151(1):100.e6-e1.
48. Madrid A, Vasquez Z, Leyton A, Mandiola C, Escobar FJ. [Short-term *Lycopersicum esculentum* consumption may increase plasma high density lipoproteins and decrease oxidative stress]. *Revista médica de Chile*. 2006;134(7):855-62.
49. Paterson E, Gordon MH, Niwat C, George TW, Parr L, Waroonphan S, et al. Supplementation with fruit and vegetable soups and beverages increases plasma carotenoid concentrations but does not alter markers of oxidative stress or cardiovascular risk factors. *The Journal of nutrition*. 2006;136(11):2849-55.
50. Riso P, Visioli F, Grande S, Guarnieri S, Gardana C, Simonetti P, et al. Effect of a tomato-based drink on markers of inflammation, immunomodulation, and oxidative stress. *Journal of agricultural and food chemistry*. 2006;54(7):2563-6.
51. Sánchez-Moreno C, Cano MP, de Ancos B, Plaza L, Olmedilla B, Granada F, et al. Mediterranean vegetable soup consumption increases plasma vitamin C and decreases F₂-isoprostanes, prostaglandin E₂ and monocyte chemoattractant protein-1 in healthy humans. *The Journal of nutritional biochemistry*. 2006;17(3):183-9.
52. Zhao X, Aldini G, Johnson EJ, Rasmussen H, Kraemer K, Woolf H, et al. Modification of lymphocyte DNA damage by carotenoid supplementation in postmenopausal women. *The American journal of clinical nutrition*. 2006;83(1):163-9.
53. Blum A, Monir M, Khazim K, Peleg A, Blum N. Tomato-rich (Mediterranean) diet does not modify inflammatory markers. *Clinical and investigative medicine Medecine clinique et experimentale*. 2007;30(2):E70-4.
54. Bose KS, Agrawal BK. Effect of lycopene from cooked tomatoes on serum antioxidant enzymes, lipid peroxidation rate and lipid profile in coronary heart disease. *Singapore medical journal*. 2007;48(5):415-20.
55. Neyestani T, Shariatzadeh N, Gharavi A, Kalayi A, Khalaji N. Physiological dose of lycopene suppressed oxidative stress and enhanced serum levels of immunoglobulin M in patients with Type 2 diabetes mellitus: a possible role in the prevention of long-term complications. *Journal of endocrinological investigation*. 2007;30(10):833-8.
56. Silaste ML, Alfthan G, Aro A, Kesaniemi YA, Horkko S. Tomato juice decreases LDL cholesterol levels and increases LDL resistance to oxidation. *The British journal of nutrition*. 2007;98(6):1251-8.
57. Denniss SG, Haffner TD, Kroetsch JT, Davidson SR, Rush JWE, Hughson RL. Effect of short-term lycopene supplementation and postprandial dyslipidemia on plasma antioxidants and biomarkers of endothelial health in young, healthy individuals. *Vascular Health and Risk Management*. 2008;4(1):213-22.
58. Devaraj S, Mathur S, Basu A, Aung HH, Vasu VT, Meyers S, et al. A dose-response study on the effects of purified lycopene supplementation on biomarkers of oxidative stress. *Journal of the American College of Nutrition*. 2008;27(2):267-73.
59. Lee C-YJ, Isaac HB, Huang SH, Long LH, Wang H, Gruber J, et al. Limited antioxidant effect after consumption of a single dose of tomato sauce by young males, despite a rise in plasma lycopene. *Free radical research*. 2009;43(6):622-8.
60. Markovits N, Ben Amotz A, Levy Y. The effect of tomato-derived lycopene on low carotenoids and enhanced systemic inflammation and oxidation in severe obesity. *The Israel Medical Association journal: IMAJ*. 2009;11(10):598-601.
61. Paran E, Novack V, Engelhard YN, Hazan-Halevy I. The effects of natural antioxidants from tomato extract in treated but uncontrolled hypertensive patients. *Cardiovascular drugs and therapy*. 2009;23(2):145-51.

62. Ried K, Frank OR, Stocks NP. Dark chocolate or tomato extract for prehypertension: a randomised controlled trial. *BMC Complementary and Alternative Medicine*. 2009;9:22-.
63. Kim JY, Paik JK, Kim OY, Park HW, Lee JH, Jang Y, et al. Effects of lycopene supplementation on oxidative stress and markers of endothelial function in healthy men. *Atherosclerosis*. 2011;215(1):189-95.
64. Shidfar F, Froghifar N, Vafa M, Rajab A, Hosseini S, Shidfar S, et al. The effects of tomato consumption on serum glucose, apolipoprotein B, apolipoprotein A-I, homocysteine and blood pressure in type 2 diabetic patients. *International journal of food sciences and nutrition*. 2011;62(3):289-94.
65. Stangl V, Kuhn C, Hentschel S, Jochmann N, Jacob C, Bohm V, et al. Lack of effects of tomato products on endothelial function in human subjects: results of a randomised, placebo-controlled cross-over study. *The British journal of nutrition*. 2011;105(2):263-7.
66. Burton-Freeman B, Talbot J, Park E, Krishnankutty S, Edirisinghe I. Protective activity of processed tomato products on postprandial oxidation and inflammation: a clinical trial in healthy weight men and women. *Molecular nutrition & food research*. 2012;56(4):622-31.
67. Thies F, Masson LF, Rudd A, Vaughan N, Tsang C, Brittenden J, et al. Effect of a tomato-rich diet on markers of cardiovascular disease risk in moderately overweight, disease-free, middle-aged adults: a randomized controlled trial. *The American journal of clinical nutrition*. 2012;95(5):1013-22.
68. Xaplanteris P, Vlachopoulos C, Pietri P, Terentes-Printzios D, Kardara D, Alexopoulos N, et al. Tomato paste supplementation improves endothelial dynamics and reduces plasma total oxidative status in healthy subjects. *Nutrition research*. 2012;32(5):390-4.
69. Abete I, Perez-Cornago A, Navas-Carretero S, Bondia-Pons I, Zulet MA, Martinez JA. A regular lycopene enriched tomato sauce consumption influences antioxidant status of healthy young-subjects: A crossover study. *Journal of Functional Foods*. 2013; 5(1):28-35.
70. Cuevas-Ramos D, Almeda-Valdés P, Chávez-Manzanera E, Meza-Arana CE, Brito-Córdova G, Mehta R, et al. Effect of tomato consumption on high-density lipoprotein cholesterol level: a randomized, single-blinded, controlled clinical trial. *Diabetes, metabolic syndrome and obesity: targets and therapy*. 2013;6:263.
71. Ghavipour M, Saedisomeolia A, Djalali M, Sotoudeh G, Eshraghyan MR, Moghadam AM, et al. Tomato juice consumption reduces systemic inflammation in overweight and obese females. *British Journal of Nutrition*. 2013;109(11):2031-5.
72. McEneny J, Wade L, Young IS, Masson L, Duthie G, McGinty A, et al. Lycopene intervention reduces inflammation and improves HDL functionality in moderately overweight middle-aged individuals. *The Journal of nutritional biochemistry*. 2013;24(1):163-8.
73. Tsitsimpikou C, Tsarouhas K, Kioukia-Fougia N, Skondra C, Fragkiadaki P, Papalexis P, et al. Dietary supplementation with tomato-juice in patients with metabolic syndrome: a suggestion to alleviate detrimental clinical factors. *Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association*. 2014;74:9-13.
74. Burton-Freeman B, Edirisinghe I, Cappozzo J, Banaszewski K, Giordano R, Kappagoda CT, et al. Processed tomato products and risk factors for cardiovascular disease. *Nutrition and Aging*. 2016;3(2-4):193-201.
75. Hsiao G, Wang Y, Tzu NH, Fong TH, Shen MY, Lin KH, et al. Inhibitory effects of lycopene on in vitro platelet activation and in vivo prevention of thrombus formation. *The Journal of laboratory and clinical medicine*. 2005;146(4):216-26.
76. Safari MR. Effects of Lycopene on the Susceptibility of Low-Density Lipoproteins to Oxidative Modification.

- Iranian Journal of Pharmaceutical Research. 2007;6(3):173-7.
77. Hung C-F, Huang T-F, Chen B-H, Shieh J-M, Wu P-H, Wu W-B. Lycopene inhibits TNF- α -induced endothelial ICAM-1 expression and monocyte-endothelial adhesion. *European Journal of Pharmacology*. 2008;586(1-3):275-82.
78. Tang X, Yang X, Peng Y, Lin J. Protective effects of lycopene against H₂O₂-induced oxidative injury and apoptosis in human endothelial cells. *Cardiovascular drugs and therapy*. 2009; 23(6):439-48.
79. Palozza P, Simone R, Catalano A, Boninsegna A, Böhm V, Fröhlich K, et al. Lycopene prevents 7-ketocholesterol-induced oxidative stress, cell cycle arrest and apoptosis in human macrophages. *The Journal of nutritional biochemistry*. 2010;21(1):34-46.
80. Palozza P, Simone R, Catalano A, Parrone N, Monego G, Ranelletti FO. Lycopene regulation of cholesterol synthesis and efflux in human macrophages. *The Journal of nutritional biochemistry*. 2011;22(10):971-8.
81. Di Tomo P, Canali R, Ciavardelli D, Di Silvestre S, De Marco A, Giardinelli A, et al. β -Carotene and lycopene affect endothelial response to TNF- α reducing nitro-oxidative stress and interaction with monocytes. *Molecular nutrition & food research*. 2012;56(2):217-27.
82. Sung LC, Chao HH, Chen CH, Tsai JC, Liu JC, Hong HJ, et al. Lycopene inhibits cyclic strain-induced endothelin-1 expression through the suppression of reactive oxygen species generation and induction of heme oxygenase-1 in human umbilical vein endothelial cells. *Clinical and experimental pharmacology & physiology*. 2015;42(6):632-9.
83. Hassan H, Edrees G. Therapeutic effect of lycopene-rich tomato juice on cardiac disorder in rats fed on fried food in oxidized frying oil. *Egypt J Hosp Med*. 2004;14:115-26.
84. Bansal P, Gupta SK, Ojha SK, Nandave M, Mittal R, Kumari S, et al. Cardioprotective effect of lycopene in the experimental model of myocardial ischemia-reperfusion injury. *Molecular and cellular biochemistry*. 2006;289(1-2):1-9.
85. Sahin N, Sahin K, Onderci M, Karatepe M, Smith M, Kucuk O. Effects of Dietary Lycopene and Vitamin E on Egg Production, Antioxidant Status and Cholesterol Levels in Japanese Quail. *Asian-Australasian Journal of Animal Sciences*. 2006;19(2):224-30.
86. Frederiksen H, Rasmussen SE, Schrøder M, Bysted A, Jakobsen J, Frandsen H, et al. Dietary supplementation with an extract of lycopene-rich tomatoes does not reduce atherosclerosis in Watanabe Heritable Hyperlipidemic rabbits. *British journal of nutrition*. 2007;97(01):6-10.
87. Hu M-Y, Li Y-L, Jiang C-H, Liu Z-Q, Qu S-L, Huang Y-M. Comparison of lycopene and fluvastatin effects on atherosclerosis induced by a high-fat diet in rabbits. *Nutrition*. 2008;24(10):1030-8.
88. Kuhad A, Sharma S, Chopra K. Lycopene attenuates thermal hyperalgesia in a diabetic mouse model of neuropathic pain. *European journal of pain (London, England)*. 2008;12(5):624-32.
89. Vergheze M, Richardson J, Boateng J, Shackelford L, Howard C, Walker L, et al. Dietary lycopene has a protective effect on cardiovascular disease in New Zealand male rabbits. *J Biol Sci*. 2008; 8(2):268-77.
90. Verschuren L, Wielinga PY, van Duyvenvoorde W, Tijani S, Toet K, van Ommen B, et al. A dietary mixture containing fish oil, resveratrol, lycopene, catechins, and vitamins E and C reduces atherosclerosis in transgenic mice. *The Journal of nutrition*. 2011;141(5):863-9.
91. Lorenz M, Fechner M, Kalkowski J, Fröhlich K, Trautmann A, Böhm V, et al. Effects of lycopene on the initial state of atherosclerosis in New Zealand White (NZW) rabbits. *PloS one*. 2012;7(1):e30808.
92. Mohamadin AM, Elberry AA, Mariee AD, Morsy GM, Al-Abbasi FA. Lycopene attenuates oxidative stress and heart lysosomal damage in isoproterenol induced cardiotoxicity in

- rats: A biochemical study. Pathophysiology. 2012;19(2):121-30.
93. Ojha S, Goyal S, Sharma C, Arora S, Kumari S, Arya D. Cardioprotective effect of lycopene against isoproterenol-induced myocardial infarction in rats. Human & experimental toxicology. 2013;32(5):492-503.
94. Wang X, Lv H, Gu Y, Wang X, Cao H, Tang Y, et al. Protective effect of lycopene on cardiac function and myocardial fibrosis after acute myocardial infarction in rats via the modulation of p38 and MMP-9. Journal of molecular histology. 2014;45(1):113-20.
95. Martin-Pozuelo G, Navarro-Gonzalez I, Gonzalez-Barrio R, Santaella M, Garcia-Alonso J, Hidalgo N, et al. The effect of tomato juice supplementation on biomarkers and gene expression related to lipid metabolism in rats with induced hepatic steatosis. European journal of nutrition. 2015;54(6):933-44.
96. Vilahur G, Cubedo J, Padró T, Casaní L, Mendieta G, González A, et al. Intake of cooked tomato sauce preserves coronary endothelial function and improves apolipoprotein AI and apolipoprotein J protein profile in high-density lipoproteins. Translational Research. 2015;166(1):44-56.

How to cite this article: Hasan T, Sultana M. Lycopene and cardiovascular diseases: a review of the literature. International Journal of Research and Review. 2017; 4(1):73-86.



International Journal of Research & Review (IJRR)

Publish your research work in this journal

The International Journal of Research & Review (IJRR) is a multidisciplinary indexed open access double-blind peer-reviewed international journal published by Galore Knowledge Publication Pvt. Ltd. This monthly journal is characterised by rapid publication of reviews, original research and case reports in all areas of research. The details of journal are available on its official website (www.gkpublication.in).

Submit your manuscript by email: gkpublication2014@gmail.com OR gkpublication2014@yahoo.com